4506

Sumitomo Pharma Co., Ltd.

住友ファーマ株式会社
Pharmaceutical
Sumitomo Pharma Co., Ltd. Manufactures, purchases, and sells pharmaceutical products for medical treatment in Japan, North America, and Asia. It offers therapeutic agents for parkinson's disease, type 2 diabetes, advanced prostate cancer, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia. The company also provides atypical antipsychotic, generic products, antiepileptic, atypical antipsychotic, and carbapenem antibiotic. In addition, it offers veterinary medicines, medical devices, etc. The company has collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.
← Companies
Price
¥1,623
Market Cap
¥644.8B
Ent. Value
¥927.1B
Net Debt
−¥282.3B
Shares Out.
397.3M
P / E
27.3×
EV / EBIT
32.2×
P / Book
—
P / NCAV
N/M
Div. Yield
—
Financials
Metric FY 2024
EDINET ↗ 		FY 2023
EDINET ↗ 		FY 2022
EDINET ↗ 		FY 2021
EDINET ↗
Net Sales ¥398.8B ¥314.6B ¥555.5B ¥560.0B
Cost of Sales ¥153.4B ¥126.6B ¥178.9B ¥157.1B
Gross Profit ¥245.4B ¥188.0B ¥376.6B ¥402.9B
SG&A ¥180.6B ¥429.5B ¥373.3B ¥249.1B
Operating Income ¥28.8B ¥-354.9B ¥-77.0B ¥60.2B
Non-Operating Income ¥2.3B ¥36.0B ¥32.2B ¥25.8B
Non-Operating Expenses ¥13.5B ¥4.3B ¥3.2B ¥3.0B
Pre-tax Income ¥17.6B ¥-323.1B ¥-47.9B ¥83.0B
Net Income (owners) ¥23.6B ¥-315.0B ¥-74.5B ¥56.4B
Minority Interest ¥1M ¥40M ¥-22.2B ¥-15.8B
Comprehensive Income ¥13.4B ¥-250.3B ¥-35.1B ¥28.2B
EBITDA ¥54.4B ¥-317.1B ¥-35.7B ¥98.6B
EPS ¥59.49 ¥-792.79 ¥-187.55 ¥141.99
Shares Outstanding 397.3M 397.3M 397.3M 397.3M
Shares Issued (total) 397.9M 397.9M 397.9M 397.9M
Treasury Shares 0.6M 0.6M 0.6M 0.6M